Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TARRYTOWN, N.Y., May 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has granted an exclusive license to Bayer for the development and...
-
TARRYTOWN, N.Y., April 21, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate...
-
TARRYTOWN, N.Y., April 06, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating...
-
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
RELISTOR® Net Sales Increased to $23.0 Million for the Fourth Quarter Oral RELISTOR Remains On-track for April 19, 2016 PDUFASubcutaneous RELISTOR Approved in Europe for All Opioid-Induced...
-
TARRYTOWN, N.Y., March 09, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced...
-
Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2015 Financial Results Call for March 11
TARRYTOWN, N.Y., March 01, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
-
TARRYTOWN, N.Y., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced...
-
TARRYTOWN, N.Y., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404,...
-
TARRYTOWN, N.Y., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has completed enrollment in its Phase 2b clinical trial of its ultra-orphan...
-
TARRYTOWN, N.Y., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced appointment of Patrick Fabbio as Chief Financial Officer. Mr. Fabbio, the...